Most Medical Affairs functions are brought into patient engagement late — as a compliance checkpoint rather than a strategic owner. That is the wrong model. When a support programme is designed to influence treatment outcomes, Medical cannot sit on the sidelines. This work helps Medical Affairs leadership define what ownership actually means, build the internal case for it, and structure the brief for the specialist partners — clinical, regulatory, and evidence — who deliver the technical components.
→ Define what Medical Affairs ownership of Supported Treatment actually means in practice: where authority sits, how it interfaces with Commercial, Digital, and Regulatory, and what governance structures protect the programme from budget cycles and brand transitions
→ Build the internal case for Medical Affairs leadership of Supported Treatment — framed for the CMO, CCO, and Board — making the strategic and commercial argument for why this is a Medical function, not a commercial one
→ Map the organisational design question: whether Medical Affairs leads directly, co-owns with Commercial, or holds scientific governance while Commercial manages execution — and what each model requires to function
→ Develop the brief for clinical and regulatory specialist partners: what evidence generation objectives the programme needs to meet, what outcome endpoints matter, and what the bar is for label-relevant data — without overstepping into study design itself
→ Advise on how to select and manage the right specialist partners — regulatory consultancies, CROs, evidence strategy advisors — and how to structure those relationships so Medical Affairs retains strategic ownership
→ Define the governance framework for real-world data capture: what data the programme should generate, how it feeds back into Medical strategy, payer discussions, and HTA submissions, and who owns the interpretation
→ Develop the Medical-to-Commercial handshake: how Medical evidence and programme outcomes translate into commercial messaging and field tools without losing scientific integrity or creating compliance risk
→ Advise on the HCP and KOL engagement model — how Medical Affairs positions the Supported Treatment programme as a clinical tool with prescribers, nurses, and patient organisations, rather than a commercial service
→ Prepare Medical Affairs leadership for executive and Board-level discussions on Supported Treatment investment: how to frame the governance case, the evidence rationale, and the long-term competitive argument in language that lands with a C-suite audience
→ Support the transition from pilot to governed capability: what Medical Affairs needs to put in place — ownership, funding, outcome KPIs, and partner architecture — to move Supported Treatment from a project to a permanent corporate asset